基本信息
浏览量:459
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Professor Parker led the clinical development of radium-223, a targeted alpha-emitter for the treatment of bone metastases. The ALSYMPCA trial demonstrated that radium-223 improves overall survival and quality of life in men with advanced prostate cancer and has a favourable safety profile.
He also led the Medical Research Council STAMPEDE RT/M1 comparison. The results showed that prostate radiotherapy improves overall survival in men with low burden metastatic disease.
He also led the Medical Research Council STAMPEDE RT/M1 comparison. The results showed that prostate radiotherapy improves overall survival in men with low burden metastatic disease.
研究兴趣
论文共 548 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
C C Parker,P M Petersen, A D Cook,N W Clarke,C Catton,W R Cross,H Kynaston,W R Parulekar,R A Persad,F Saad,L Bower, G C Durkan,
Annals of oncology : official journal of the European Society for Medical Oncologyno. 7 (2024): 656-666
Nature Chemical Biologyno. 2 (2024): 261-261
European Radiologyno. 2 (2024): 1146-1154
C.C. Parker,P.M. Petersen, A.D. Cook,N.W. Clarke,C. Catton,W.R. Cross,H. Kynaston,W.R. Parulekar,R.A. Persad,F. Saad,L. Bower, G.C. Durkan,
Annals of Oncology (2024)
biorxiv(2024)
Nature chemical biologyno. 7 (2024): 823-834
NATURE REVIEWS METHODS PRIMERSno. 1 (2024): 1-23
LANCETno. 10442 (2024): 2416-2425
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn